You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
創勝集團-B(06628.HK):人源化抗VEGFR-2單克隆抗體MSB0254成功完成Ib期臨牀試驗首例患者給藥
格隆匯 11-24 21:22

格隆匯11月24日丨創勝集團-B(06628.HK)宣佈,其人源化抗VEGFR-2單克隆抗體MSB0254成功完成Ib期臨牀試驗首例患者給藥。此前該藥物已完成Ia期臨牀試驗,確定了二期臨牀試驗推薦劑量("二期臨牀試驗推薦劑量")。本研究旨在評估MSB0254在二期臨牀試驗推薦劑量下在多種類型實體瘤中的安全性、耐受性、藥代動力學(PK)特徵及抗腫瘤療效,包括神經內分泌腫瘤和肝細胞癌等。

抑制血管生成通路作為治療癌症的有效方法已得到充分驗證,且在調節免疫微環境和增強免疫療法的活性方面也具有良好前景。公司將探索MSB0254作為單藥和與其他藥物聯用治療多種類型實體瘤的潛在抗腫瘤作用,其中包括公司管線中的TST001和TST005。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account